Sweden's Moberg Pharma Q2 loss narrows as revenue rises

Moberg Pharma AB (publ)

13/08/2026 07:09

Overview
Sweden specialty pharma firm's Q2 revenue rose yr/yr, and operating loss narrowed
Company expanded licensing deal with Karo Healthcare to APAC and China
First European trademark approvals enable launch preparations to proceed as planned

Outlook
Moberg Pharma plans first European deliveries of MOB-015 around year-end
Company expects first patients in Israel to access MOB-015 during Q3
Moberg Pharma to launch MOB-015 in China via cross-border e-commerce in parallel with Europe

Result Drivers
INTERNATIONAL EXPANSION - Co cited expanded licensing agreements with Karo Healthcare in APAC and China as key to broadening its market reach
TRADEMARK APPROVALS - Approvals in first European countries enabled launch preparations and commercial activities to proceed as planned
NORDIC MARKET PERFORMANCE - Terclara maintained leading value and unit shares in Sweden and Norway, supporting revenue growth

Company press release: ID:nWkr1fdz9C

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
SEK 5.8 mln
 
Q2 Loss Per Share
 
SEK 0.07
 
Q2 Net Loss
 
SEK 3.30 mln
 
Q2 EBIT
 
-SEK 4.70 mln
 
Q2 EBITDA
 
-SEK 4.30 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Moberg Pharma AB (publ) is SEK14.00, about 22.8% above its August 12 closing price of SEK11.40

Reuters Recommended Reads
Aug 12 - Sweden's Magle Chemoswed Q2 revenue rises on improved production efficiencies
Aug 13 - Denmark's Zealand Pharma H1 revenue, profit fall sharply
Aug 12 - Israel's Kamada Q2 revenue beats estimates on KEDRAB growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)